State Street SPDR S&P Biotech ETF
635 hedge funds and large institutions have $7.94B invested in State Street SPDR S&P Biotech ETF in 2021 Q3 according to their latest regulatory filings, with 55 funds opening new positions, 224 increasing their positions, 186 reducing their positions, and 72 closing their positions.
20% more repeat investments, than reductions
Existing positions increased: 224 | Existing positions reduced: 186
18% more funds holding in top 10
Funds holding in top 10: 17 → 20 (+3)
4% less funds holding
Funds holding: 663 → 635 (-28)
7% less ownership
Funds ownership: 118.08% → 111.08% (-7%)
12% less capital invested
Capital invested by funds: $9.05B → $7.94B (-$1.1B)
24% less first-time investments, than exits
New positions opened: 55 | Existing positions closed: 72
54% less call options, than puts
Call options by funds: $1.5B | Put options by funds: $3.28B
Top Buyers
Top Sellers
| 1 |
Citigroup
New York
|
-$395M |
| 2 |
JP Morgan Chase
New York
|
-$246M |
| 3 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$168M |
| 4 |
Morgan Stanley
New York
|
-$83.5M |
| 5 |
Canada Pension Plan Investment Board
Toronto Ontario,
Ontario, Canada
|
-$77.3M |
XBI Hedge Fund Activity: Q3 2021 in Review
635 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2021, worth a combined $7.94B — down 12% from $9.05B a quarter earlier.
Sellers outnumbered buyers: 72 funds closed out of XBI and 55 opened new positions — a net loss of 17 holders — while 186 trimmed existing stakes and 224 added.
The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, adding an estimated $164M. The largest seller was Citigroup, cutting an estimated $395M.
- 635 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2021, down from 663 in Q2 2021.
- Funds reported $7.94B of State Street SPDR S&P Biotech ETF stock for Q3 2021, down 12% quarter-over-quarter.
- 55 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2021 and 72 closed out, a net change of -17 holders.
- The largest State Street SPDR S&P Biotech ETF buyer in Q3 2021 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $164M added.
- The largest State Street SPDR S&P Biotech ETF seller in Q3 2021 was Citigroup, an estimated $395M sold.
Based on aggregated 13F filings for Q3 2021.